Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising ...

Corvus Pharmaceuticals highlighted significant progress for soquelitinib, including ongoing Phase 3 trials for T-cell lymphoma and advancements in atopic dermatitis studies. The company has ...

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek ...

(RTTNews) - Corvus Pharmaceuticals, Inc.(CRVS), a clinical-stage biopharmaceutical company, Thursday reported positive data from its Phase 1/1b study of soquelitinib for the treatment of patients ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Honeywell (Nasdaq: HON) has announced that its SwiftDecoder barcode-decoding software will be integrated into Corvus Robotics’ autonomous inventory drones. This partnership aims to enhance ...